Contineum Therapeutics, Inc. (CTNM) Insider Ownership

Historic Ownership Trends

There are no significant Insider Shareholders in Contineum Therapeutics as of December 12, 2025.

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares Report Date
Daniel S. Lorrain Chief Scientific Officer 168,562 27 Nov, 2024
Venture Capital Vi, L.P. Versant 148,312 11 Apr, 2024
Stephen L. Huhn Cmo & Sr VP And Clinical Dev. 12,800 14 Aug, 2024

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
25 Nov, 2024 Daniel S. Lorrain Class A Common Stock D 1,010 $16.02 168,562 D S
18 Nov, 2024 Daniel S. Lorrain Class A Common Stock D 6,091 $16.37 169,671 D S
18 Nov, 2024 Daniel S. Lorrain Class A Common Stock D 99 $17.05 169,572 D S
13 Aug, 2024 Stephen L. Huhn Class A Common Stock A 12,800 $1.01 12,800 D M
13 Aug, 2024 Stephen L. Huhn - - 12,800 D
09 Apr, 2024 Venture Capital Vi, L.P. Versant - - 391,785 I
09 Apr, 2024 Venture Capital Vi, L.P. Versant Class A Common Stock A 391,785 - 391,785 I C
09 Apr, 2024 Venture Capital Vi, L.P. Versant - - 2,531 I
09 Apr, 2024 Venture Capital Vi, L.P. Versant Class A Common Stock A 2,531 - 2,531 I C
09 Apr, 2024 Venture Capital Vi, L.P. Versant Class A Common Stock A 148,312 - 148,312 I C
09 Apr, 2024 Venture Capital Vi, L.P. Versant - - 148,312 I